← Russell 3000 cross-section

EMBC Embecta Corp.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$276m
Revenue TTM
$1.0bn
Net income TTM
$88m
Free cash flow
$165m
Composite score
68.8
Sector rank
#2709

Valuation

P / E
3.2
EV / EBITDA
5.1
EV / sales
1.4
FCF yield
59.59%
Earnings yield vs 10-yr
26.95pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
8.6%
EBITDA margin
26.3%
ROE
-14.3%
ROIC
45.8%
Revenue growth
-7.6%

Insider activity, last 90 days

Net open-market
$0.56m
Buyers
4
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We will also make a payment of up to £50.0 million upon the achievement of certain commercial milestones related to sales of the Aidaptus® next-generation auto-injector platform. Results of Operations Our unaudited Condensed Consolidated Statements of Income are as follows: Three Months Ended June 30, 2026 Summary (on a comparative basis) Key financial results for the three months ended June 30, 2026 were as follows: • Revenue decreased by $23.8 million to $271.7 million from $295.5 million; • Gross profit decreased by $43.8 million to $153.3 million from $197.1 million. …Embecta Corp., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →